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Background and purpose: The aim of this study is to assess the toxicity and cosmetic outcome of preop-
erative accelerated partial breast irradiation (PAPBI) for breast cancer patients with low risk on local
recurrence.
Material and methods: Women aged P60 years with an invasive, unifocal 63 cm on MRI, (non-lobular)
adenocarcinoma of the breast and a negative sentinel node received PAPBI (40 Gray in 10 fractions over
2 weeks). Six weeks after radiotherapy a wide local excision was performed.
Results: 70 patients with a median follow-up of 23 months (3–44 months) were evaluated. The overall
postoperative infection rate was 11%. At 1, 2 and 3 years of follow-up respectively 89%, 98% and 100%
of patients had no or mild induration-ﬁbrosis. Fibrosis was only found in a small volume of the breast.
The global cosmetic outcome was good to excellent in 77% at 6 months to 100% at 3 years. Two patients
developed a local recurrence.
Conclusion: Our ﬁrst results show limited ﬁbrosis in a small volume and good to excellent cosmetic out-
come. In selected patients, preoperative radiotherapy appears to be a good option for breast conserving
therapy.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 114 (2015) 322–327
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).After breast-conserving therapy (BCT) for the treatment of inva-
sive breast cancer most ipsilateral local recurrences occur at or
close to the original tumor site [1,2]. Therefore, accelerated partial
breast irradiation (APBI) has been studied as an alternative to
whole breast irradiation (WBI) for patients with low-risk for local
recurrence [3,4]. With APBI radiotherapy (RT) is only targeted to
the surgical cavity and a limited area of surrounding tissue instead
of the whole breast. Also, a higher dose to a smaller volume can be
delivered in a shorter period of time.Several methods of APBI have been developed: the frequently
used invasive techniques including intraoperative radiotherapy
(IORT), interstitial or intracavitary brachytherapy and the non-in-
vasive three-dimensional conformal external-beam radiation
(3D-CRT). The invasive methods normally treat smaller volumes
of normal tissue compared with 3D-CRT APBI, but a disadvantage
of IORT is that pathology information at time of the irradiation is
absent, including information about tumor free margins. Since
the tumor is often not centrally located in the surgical resection
specimen, this may lead to under- or overtreatment of the target
area [5,6]. Advantages of postoperative 3D-CRT APBI are the avail-
ability of pathology information at the time of treatment, opti-
mization of the radiotherapy plan and more dose homogeneity,
which can lead to less radiotherapy side effects including ﬁbrosis.
Furthermore, it is widely available, less physician-dependent, non-
invasive and accessible to large groups of patients.
Several studies on postoperative 3D-CRT APBI showed variable
results concerning toxicity and cosmetic outcome [7–11]. The
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Large inter-observer variability in deﬁning the tumor bed for post-
operative irradiation has been shown in many studies, resulting in
larger irradiated volumes [12–14].
In a previous study we showed less inter-observer variation in
tumor delineation preoperatively compared to postoperatively
[15]. When RT is given preoperatively more accurate tumor delin-
eation can be performed. After RT surgery is performed, thereby
removing the area of the breast that received the highest RT dose.
As a result, limited ﬁbrosis and a good cosmetic result are
expected.
In the multi-center phase II preoperative accelerated partial
breast irradiation (PAPBI) trial (registered with ClinicalTrials.gov,
Number NCT01024582) low risk patients of 60 years and older
are irradiated preoperatively instead of postoperatively with exter-
nal beam APBI. In total 120 patients will be included in the trial. In
this paper we present the results of the interim-analysis of the ﬁrst
70 patients. This interim-analysis was carried out in order to allow
continuation of this trial, taking into account treatment complica-
tions, local control and cosmetic outcome. The main objective is to
investigate the impact on local control, cosmesis and breast ﬁbrosis
of a short fractionated schedule given preoperatively.
Patients and methods
The PAPBI trial started in April 2010 at the Netherlands Cancer
Institute-Antoni van Leeuwenhoek (NKI-AVL) in the Netherlands.
Other institutes joined the trial later: Institut Gustave Roussy
(IGR) in France, Karolinska Institutet in Sweden and University
Medical Centre Utrecht (UMCU) in The Netherlands.Patients
Patients were eligible for the PAPBI trial if they met the follow-
ing criteria: ageP60 years; cT1–2 (tumor size 63 cm) on magnetic
resonance imaging (MRI); histologically proven adenocarcinoma;
unifocal lesion on mammogram and MRI; pN0 (determined by a
sentinel node procedure before start of RT); ECOG performance
scale 62. Patients were excluded in case of extensive microcalciﬁ-
cations on mammogram; ductal carcinoma in situ of the breast,
without invasive tumor; lobular invasive breast cancer; treatment
prior to radiotherapy; a planning target volume (PTV)/ipsilateral
breast ratio >25%. Also, patients with a previous history of malig-
nancy or synchronous malignant tumor in the other breast were
excluded with the exception of pT1N0 contralateral breast carcino-
ma more than 5 years previously, basal cell carcinoma of the skin
and adequately treated carcinoma in situ of the cervix. Written
informed consent was obtained prior to start of the treatment pro-
tocol. The institutional review boards of the participating centers
approved the study protocol.Treatment and trial procedures
Prior to RT, tumor biopsies were taken for histopathological
evaluation by a breast pathologist. At the time of the biopsies a
marker was placed in the tumor, which was used for daily setup
veriﬁcation as well as guidance for the surgeon during the opera-
tion. RT consisted of 10 fractions of 4 Gray over 2 weeks. The gross
target volume (GTV) was deﬁned as the visible tumor on the plan-
ning computed tomography (CT) scan using additional information
fromMRI, mammogram and ultrasound. The clinical target volume
(CTV) was constructed by extending the GTV with 2 cm. The PTV
was constructed by extending the CTV with 0.5 cm. Dose distribu-
tions were planned according to the International Commission on
Radiation Units and Measurements recommendations. Position
veriﬁcation was performed by cone-beam CT-scan or ElectronicPortal Imaging according to the institutes’ protocol. Conformal
3D CRT, Intensity Modulated Radiotherapy (IMRT) or Volumetric
Modulated Arc Therapy (VMAT) were used as RT techniques,
depending on the institute. Six weeks after the last day of RT, a
wide local excision was performed. In case of positive resection
margins a re-excision was performed. Adjuvant systemic treat-
ment was applied according to local guidelines in the participating
institutes (based on tumor size on MRI and histological grading of
the tumor on biopsies). To evaluate response to RT, MRI was per-
formed prior to the start and six weeks after completion. A 18F-
ﬂuorodeoxyglucose positron emission tomography (PET)-scan
was optional and was performed at the same time as MRI.Outcomes
The primary endpoints were local recurrence, breast ﬁbrosis
and cosmetic outcome. Local recurrences should not exceed 4% at
5 years of follow-up.
An additional goal was to develop a classiﬁer that predicts
radiosensitivity. For this translational research gene expression
proﬁling of the tumor will be correlated to response of the tumor
as measured by pathologic response, MRI and PET-scan 6 weeks
after irradiation.Statistical design
The calculation of the number of patients to be included for the
full phase II trial was based on the amount needed to develop a
gene expression signature for radiosensitivity. It was estimated
that 60 patients were needed in the training set. The classiﬁer
was considered to be clinically useful if the positive predictive val-
ue was >90% and the negative predictive value was >50%. Based on
the assumption that the proportion of responders and non-respon-
ders would be close to 50% the number of patients needed in the
validation set was 50. In total 120 patients will be included in
the trial.Follow up
During RT acute skin toxicity (up to 1 month after treatment)
was scored by the attending radiation oncologist or trained physi-
cian assistant according to the EORTC/RTOG acute radiation mor-
bidity scoring scale. After RT, patients underwent clinical
evaluation every 3 months in the ﬁrst year. Thereafter, follow-up
visits were conducted every 6 months and annually after 5 years.
Patients underwent a screening mammography annually and in
the ﬁrst year of follow-up with an additional MRI. Postoperative
complications were scored for all patients.
At each visit clinical induration was scored separately for the
tumor bed area and the whole breast. Induration was used as a sur-
rogate of the effect after radiotherapy and surgery (edema and
ﬁbrosis) [16,17]. After 24 months induration was considered to
be ﬁbrosis. Also breast pain, rib pain and the presence of rib frac-
ture(s) were evaluated according to the EORTC/RTOG/late radiation
morbidity scoring.
Cosmesis was evaluated by the physician before start of RT,
6 months after completion of treatment and thereafter every year.
The treated breast was compared to the contralateral breast for
visible sequelae, telangiectasia and global cosmetic result scored
as (0) excellent, (1) good, (2) fair, (3) poor or (4) not evaluable.
Dutch patients received a questionnaire concerning cosmetic out-
come yearly. Digital photos of both breasts were taken before the
start of RT, 6 months after completion of treatment and thereafter
every year. The photos will be used in the future for objective
assessment of cosmetic outcome by the BCCT.core project software
program.
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Time intervals were calculated using the ﬁrst day of RT as treat-
ment day 1. Descriptive analyses were used to show the proportion
of patients with grade 0, grade 1, Pgrade 2 events at each follow-
up visit.
Patients who underwent a mastectomy due to a local recur-
rence or incomplete resection were excluded from the cosmetic
analysis after the mastectomy.Results
Patient characteristics
A total of 70 patients, treated between April 2010 and Decem-
ber 2013, were evaluated from all participating centers; NKI-AVL
(n = 47), IGR (n = 14), Karolinska (n = 6) and UMCU (n = 3). The
median follow-up was 23 months (range 3–44). The mean tumor
size was 1.5 cm (0.4–3.2). All patients were node negative, deter-
mined by a sentinel node procedure before RT. At histological
examination of the pre-treatment biopsy, ninety-four per cent of
the tumors were classiﬁed as invasive ductal carcinoma (IDC),
and the majority as histological grade 1–2 (96%), which was estro-
gen receptor (ER)/progesterone receptor (PR) positive and HER2
negative (Table 1).Start treatment
Prior to treatment TreatmentTreatment
The mean GTV was 2.7 cc (SD 2.0, range 0.1–12.0), the mean
CTV was 87 cc (SD 32, range 7–193) and the mean PTV was
121 cc (SD 42, range 13–263). The mean whole breast volume
was 1028 cc (SD 474, range 107–2265) resulting in a PTV/ipsilater-
al breast ratio of 13.3% (SD 4.9, range 5–24). None of the 70
patients interrupted or stopped the treatment. 69 Patients under-
went a wide local excision with negative resection margins. One
patient had a focally positive resection margin. A subsequent mas-
tectomy followed because a poor cosmetic result was expected
with a re-excision. 46/70 patients (66%) received adjuvant hor-
monal treatment and 4/70 patients (6%) adjuvant chemotherapy.•Three core biopsies 
•Tumor marking 
•MRI
•PET*
Radiotherapy
•10 days
•40 Gray; 10 
Surgery
6 weeks after RT
MRI
PET*Treatment-related toxicities and complications
Acute skin toxicity was scored for all 70 patients; 39 patients
(56%) had no acute toxicity, 30 patients had grade 1 (43%) and
one patient (1%) grade 2 acute skin toxicity. Postoperative compli-Table 1
Patient characteristics.
Variables Number (n = 70)
Median age (years) 67.3 (60–80)
Median tumor size (cm) 1.3 (0.4–3.2)
Histological grade biopsy
1 22 (32%)
2 44 (64%)
3 3 (4%)
Not gradable 1
Estrogen receptor
Positive 67 (96%)
Negative 3 (4%)
Progesterone receptor
Positive 53 (76%)
Negative 17 (24%)
HER2 neu-status
Positive 2 (3%)
Negative 68 (97%)cations were noted in 11 of the 70 patients (16%); two patients had
direct post-operative bleeding requiring re-surgery performed on
the same day, one patient developed a hematoma two months
after surgery and needed re-surgery, eight patients developed a
postoperative wound infection, one of whom needed re-surgery
for a wound abscess and in one patient a small ﬁstula was formed
which closed within ten months after treatment with antibiotics.
The other six patients were successfully treated with oral antibi-
otics. No other wound healing problems were observed. Seven
patients (10%) developed persistent seroma (see Fig. 1).Induration-ﬁbrosis
In four patients transient edema in the whole breast was
observed, in all other patients the breast tissue outside the irradi-
ated tumor area showed no side effects. In the ﬁrst year an increase
of induration was seen at the tumor area: from 52% (31/60
patients) to 69% (41/59 patients) to 80% (40/50 patients) after 3,
6 and 9 months respectively. Over time the proportion of patients
with (any grade of) induration-ﬁbrosis declined as well as the
grade (Fig. 2 and Supplemental Table 1). At 12 months induration
was scored for 57 patients; 11 (19%) had none, 40 (70%) mild
and six (11%) moderate induration. At 24 months 19 of 41 patients
(46%) had mild ﬁbrosis and one (2%) patient moderate ﬁbrosis. At
30 months the majority of patients (15/23 patients) had no ﬁbrosis
(65%). After 36 months ﬁbrosis was scored for only 11 patients, all
had none-mild ﬁbrosis. The area of ﬁbrosis was limited to a
clinically estimated volume of 1–2 cm.Other toxicity
During total follow-up, 27 of 70 patients (39%) reported grade 1
breast pain (transient in 21, persistent in six patients) and sevenFig. 1. Outline of investigations before and during therapy. * = optional.
Fig. 2. The grade of induration/ﬁbrosis at different time-points.
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diminished from grade 2 to grade 1 and in ﬁve patients the pain
was transient (grade 0). One patient reported grade 3 breast pain,
which had diminished to grade 2 at last follow-up date. 11 patients
(16%) reported rib pain, of whom nine scored grade 1 (six tran-
sient) and two patients grade 2 (persistent). No rib fractures were
observed.Cosmetic results
Cosmesis, as scored by the physician, improved over time (Fig. 3
and Supplemental Table 2). After 0.5 years global cosmetic out-
come was scored for 66 patients; 51 (77%) had a good to excellent,
13 (20%) a fair and two (3%) a poor cosmetic result. After 1 (n = 56),
2 (n = 41) and 3 years (n = 13) the proportion of patients with a
good to excellent cosmetic outcome was 89%, 88% and 100%
respectively. The cosmetic assessment by the Dutch patients
(n = 50) was also evaluated (Fig. 4 and Supplemental Table 3).
The majority of patients was satisﬁed to very satisﬁed with the
cosmetic result; 81%, 86%, 80% and 79% after respectively 0.5, 1,
2 and 3 years. Examples of cosmetic outcome are shown in Fig. 5.Treatment efﬁcacy
In two patients an ipsilateral tumor recurrence (IBTR) was diag-
nosed. In both cases the primary tumor was grade 1, ER/PR posi-
tive, HER2 negative; in one patient the IBTR was diagnosed at the
skin entry of the biopsy tract after 12 months, outside the radiation
ﬁeld; one patient was diagnosed with an IBTR in another quadrant
of the breast after 26 months. For both patients, the IBTR was out-Fig. 3. Physician’s cosmetic assessment over time.
Fig. 4. Patient’s questionnaire on cosmetic outcome.side the radiation ﬁeld and loss of heterozygosity-analysis showed
true recurrences. No distant failure has occurred. One patient died
due to pneumonia, not related to the breast cancer or PAPBI
treatment.
Discussion
This is, to the best of our knowledge, the ﬁrst study of preop-
erative as opposed to postoperative APBI in low risk breast cancer
patients. Seventy patients treated with preoperative APBI show
low complication rates, limited ﬁbrosis in a small volume and good
to excellent cosmetic results with an acceptable local recurrence
rate.
Despite preoperative irradiation, our postoperative complica-
tion rate compares favourably to conventional radiotherapy with
modern techniques. In the Cambridge IMRT Trial, 648 patients
were treated with BCT of which 19.7% had a postoperative infec-
tion and 7.9% postoperative hematoma [18], although lower infec-
tion rates have been reported in brachytherapy trials. We observed
an overall postoperative infection rate of 11% and a 5.7% postop-
erative hematoma rate.
The majority of the patients in the PAPBI trial had no or only
mild ﬁbrosis. During the trial it was noted that the volume of ﬁbro-
sis was very small, beyond expectation. The volume was clinically
estimated 1–2 cm in most patients, generally at the boundaries of
the previously irradiated area, suggesting a leftover of the irradiat-
ed volume. After conventional BCT with WBI, ﬁbrosis rates are
higher; in the EORTC 22881-10882 boost–no boost trial the 10 year
rate of moderate or severe ﬁbrosis increased from 13% to 28% with
a boost [19]. These rates are similar to the study of Hepel et al.,
which showed moderate to severe ﬁbrosis in 25% of the patients
after a median follow-up time of 15 months in a study of 64
patients [10]. The presence of ﬁbrosis was the strongest correlate
of a fair/poor cosmetic outcome. The results concerning toxicity
of other external beam APBI studies are varied. Several studies
show limited toxicity, comparable with our results [7–9,20,21].
In the multicenter study of Berrang et al. with a median follow-
up of 3 years, grade 2 ﬁbrosis was the most prominent late effect
and was observed in 7 of 87 patients (8%) [7].
The global cosmetic outcome, scored by the physician, was good
to excellent in 77% at 0.5 years and 100% at 3 years in our patients.
Cosmesis did not deteriorate since treatment with a tendency to
improvement over time, in contrast to other external beam APBI
trials where cosmetic outcome gets worse with longer follow up
[11,16]. Results concerning cosmetic outcome in other trials, con-
cerning postoperative RT, range from good to excellent cosmetic
outcome in 97% of the patients [22] to 21% unacceptable cosmesis
at a median follow up of 2.5 years [11]. Most published results
involve single-center studies with small numbers of patients and
short follow up. Larger trials include the RAPID trial, which showed
signiﬁcantly more poor cosmetic results at 3 years in the 3D-CRT
APBI group compared to WBI (29% versus 16.5%) [16]. The volume
of breast that receives 95% of the prescribed dose was restricted to
<35% in that trial. It was speculated that this volume may have
been too large in some patients. Hepel et al. and Jagsi et al. have
also linked their poor cosmetic results to the large volumes of
breast tissue receiving relatively high irradiation doses [10,11]. In
the trial of Hepel et al. a mean PTV/ whole breast volume of 18%
in patients with excellent/good cosmesis and 24% in patients with
fair/poor cosmesis was seen.
It is expected that preoperative external beam APBI results in
smaller treatment volumes compared to postoperative APBI
because of more accurate target deﬁnition. The mean PTV/breast
ratio in the PAPBI study was 13%. Compared to the study of Hepel
et al. the mean tumor size in the PAPBI was larger (1.5 cm in the
PAPBI versus 0.9 cm in the study of Hepel et al.). Although similar
Fig. 5. Examples of improvement over time of cosmetic outcome in 2 patients (photographs of baseline and 6, 12 and 24 months since the start of RT).
326 Preoperative partial breast irradiationCTV and PTV margins were used, we found signiﬁcantly smaller
PTV volumes in our preoperatively treated patients (mean PTV
122 cc versus 296 cc in the Hepel et al. series). This was also seen
in a study of Palta et al. [23]. A virtual plan for preoperative single
fraction external beam APBI resulted in a substantial reduction in
ipsilateral breast tissue dose compared with postoperative APBI.
Also Nichols et al. showed that preoperative APBI could decrease
the planning target volume and the dose to normal tissues com-
pared to postoperative APBI in a cohort of 40 patients [24]. Our
good cosmetic results are likely to be explained by the small irra-
diated volume (mean PTV 122 cc) and the surgical removal of the
breast tissue that received the highest radiation dose, with very
limited ﬁbrosis as a result.
Comparison between studies can be difﬁcult because varying
toxicity and cosmetic result scoring systems and dose and frac-
tionation regimens are used. For instance, we applied an RT
scheme of 10 times 4 Gray once a day while other external beam
APBI trials used schedules with RT twice a day. Furthermore, dosi-
metric constraints differ between studies. For most patients in the
PAPBI trial IMRT is used, while in other APBI trials most patients
were treated with conformal 3D-CRT.
The treatment efﬁcacy results of postoperative external beam
APBI phase I and II studies are limited and overall show low local
recurrence rates after limited follow up time [7–11]. Most long-
term data concerning APBI originate from trials using brachyther-
apy. In the study of Polgar et al. equal local control for multi-
catheter brachytherapy or electron beam irradiation after
10.2 years was observed [25,26]. Other trials that randomisedbetween external beam RT and IORT showed higher IBTR rates in
the IORT group [27,28]. In our PAPBI trial, two patients had an IBTR.
Longer follow-up is needed to conclude more about breast relapse
rates in our and other external beam APBI studies. Therefore, ade-
quate patient selection remains important [3,4].
Limitations of the current study are the non-randomized set-up
and the relatively small sample size. As a consequence of the low
number of patients and incomplete follow-up the progress of
cosmesis and ﬁbrosis must be carefully interpreted. A clinical dis-
advantage of preoperative compared to postoperative APBI, is that
a sentinel procedure has to be obtained before RT, requiring an
additional surgical procedure.
The ﬁrst results of this preoperative APBI trial show low compli-
cation rates, limited induration-ﬁbrosis in a small volume and good
to excellent cosmetic results. Preoperative APBI is a feasible and
widely available technique with promising results for low risk
breast cancer patients.Funding
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